Gilead Sciences, Inc. GILD
150.93
1.24
0.83%
as of 25 Sep
- Market cap
- $183.2B
- P/E
- 0.0×
Follow GILD
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Gilead Sciences, Inc. (GILD) P/S ratio
As of 25 September 2026, Gilead Sciences, Inc. (GILD) trades at a P/S ratio of 6.2×. Over the past ten years it has ranged from 2.6× (June 2022) to 6.6× (June 2015); the current reading is higher than 97% of that period. That is above the Drug Manufacturers General industry median of 3.3× and above the Healthcare sector median of 3.8×.
P/S ratio, daily
Annual
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 5.2× | 29.46% |
| FY2024 | 4.0× | 4.56% |
| FY2023 | 3.8× | (2.47%) |
| FY2022 | 3.9× | 17.61% |
| FY2021 | 3.3× | 12.60% |
| FY2020 | 3.0× | (19.31%) |
| FY2019 | 3.7× | 0.19% |
| FY2018 | 3.7× | (1.09%) |
| FY2017 | 3.7× | 13.53% |
| FY2016 | 3.3× | (28.01%) |
Quarterly
| Period | P/S ratio | Change |
|---|---|---|
| Jun 2026 | 5.2× | (11.42%) |
| Mar 2026 | 5.8× | 12.25% |
| Dec 2025 | 5.2× | 9.33% |
| Sep 2025 | 4.7× | (0.81%) |
| 42 more quarters | Free account |
Against its own ten years
Low 2.6×
High 6.6×
Ten-year median
3.7×
Current reading's percentile
97
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| SNY Sanofi compare | 1.7× |
| GSK GSK PLC Sponsored ADR compare | 2.2× |
| PFE Pfizer Inc. compare | 2.6× |
| BMY Bristol Myers Squibb Company compare | 2.6× |
| NVO Novo Nordisk A/S compare | 3.3× |
| AZN AstraZeneca PLC compare | 4.2× |
| NVS Novartis AG compare | 4.9× |
| AMGN Amgen Inc. compare | 5.9× |
| GILD Gilead Sciences, Inc. | 6.2× |
| Drug Manufacturers General industry median | 3.3× |
| Healthcare sector median | 3.8× |
| Market median | 2.0× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on GILD
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement